Download full-text PDF

Source

Publication Analysis

Top Keywords

2006 annual
4
annual education
4
education meeting
4
meeting spondyloarthritis
4
spondyloarthritis therapy
4
therapy network
4
network spartan
4
0
1
education
1
meeting
1

Similar Publications

A comprehensive analysis of serotype-specific invasive capacity, clinical presentations, and mortality trends of invasive pneumococcal disease.

Vaccine

January 2025

Department of Pediatrics, Section of Infectious Diseases and Global Health, Yale University School of Medicine, New Haven, CT, United States; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, United States; Yale Institute for Global Health, Yale University, New Haven, CT, United States; Yale Center for Infection and Immunity, Yale University, New Haven, CT, United States. Electronic address:

Background: Pneumococcal conjugate vaccines (PCV) reduced invasive disease, but the overall prevalence of pneumococcal nasopharyngeal colonization among children has not changed significantly. Our knowledge of which serotypes, once colonized, hold a higher likelihood to cause invasive disease is limited.

Methods: Serotype-specific invasive capacity (IC) of Streptococcus pneumoniae was estimated using an enhanced population-based invasive pneumococcal disease (IPD) surveillance in children <7 years of age in Massachusetts and surveillance of nasopharyngeal (NP) colonization in selected Massachusetts communities in corresponding respiratory seasons.

View Article and Find Full Text PDF

Background: Postneonatal cerebral palsy (PNCP) is rare and requires large databases to be studied over time.

Objectives: To study the time trend of prevalence of PNCP overall and by cause, and to describe the clinical characteristics of children with PNCP according to cause and compared with children with pre/peri/neonatal CP (PPNCP).

Methods: The Surveillance of Cerebral Palsy in Europe (SCPE) database was used.

View Article and Find Full Text PDF

This study aimed to evaluate the annual pollution characteristics of trichloromethane (TCM) in Kunshan City's tap water from 2016 to 2022. This research analyzed 566 tap water samples from centralized water supply units, utilizing the GB 5749-2006 Sanitary Standard for Drinking Water as the evaluation benchmark. Data analysis employed non-parametric tests and Spearman's correlation analysis using Excel 2017 and SPSS 26.

View Article and Find Full Text PDF

Import of global high-risk clones is the primary driver of carbapenemase-producing in Norway.

J Med Microbiol

January 2025

Norwegian Centre for Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Troms, Norway.

Infections by carbapenemase-producing (CP-Pa) are concerning due to limited treatment options. The emergence of multidrug-resistant (MDR) high-risk clones is an essential driver in the global rise of CP-Pa. Insights into the molecular epidemiology of CP-Pa are crucial to understanding its clinical and public health impact.

View Article and Find Full Text PDF
Article Synopsis
  • Lung cancer is the most prevalent and deadliest cancer globally, often detected late, which limits treatment options and worsens outcomes; advancements in nanotechnology offer promising approaches for earlier diagnosis through nanoparticles.
  • The study used bibliometric tools to analyze 966 articles on this topic from 2006 to 2023, revealing an increasing trend in research, with China leading in publications, followed by the U.S. and India, and highlighting key areas of focus such as biomarkers and gold/silver nanoparticles.
  • This research provides valuable insights into existing literature and trends, aiding scholars in understanding the landscape of nanoparticles in lung cancer research and guiding future experimental designs.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!